Market Overview

Why Cancer Genetics Is Trading Higher Today

Why Cancer Genetics Is Trading Higher Today

Cancer Genetics (NASDAQ: CGIX) shares are trading higher on Monday after the company announced the entry into a definitive merger agreement with StemoniX.

Cancer Genetics is in the early stage of precision medicine, enabling individualized therapies in the field of oncology through diagnostic products and services and molecular markers. The company develops, commercializes and provides molecular- and biomarker-based tests and services that enable physicians to personalize the clinical management of each individual patient by providing genomic information to diagnose, monitor and inform cancer treatment.

It also enables biotech and pharmaceutical companies to select candidate populations and reduce adverse drug reactions by providing information regarding genomic factors influencing subject responses to therapeutics. The company derives most of its revenue from the United States.

Cancer Genetics shares were trading up 130.24% at $6.70 on Monday during the time of publication. The stock has a 52-week high of $10.39 and a 52-week low of $1.92.


Related Articles (CGIX)

View Comments and Join the Discussion!

Posted-In: why it's movingM&A News

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at